Early Access — free while we kick the tires
EdgarHawk

LEDESMA BRUCE

Chief Legal & Compliance Ofc

Officer
2 filings analyzed · 1 company · Latest 2025-05-30

Companies

Company Buys Sells Direction
Nextracker Inc. NXT 0 2 Net selling

Activity

May 2025
2025-05-30 Nextracker Inc. NXT
medium
Sell
83,561 shares
$4,655,434
Significance 6/10

CLO Bruce Ledesma sold 83,561 shares of NXT at $55.71 (2025-05-29); post-sale holdings: 195,790 shares (-29.9%)

Ledesma sold 83.6K shares for $4.7M at $55.71, reducing his NXT position by 29.9% to 195.8K shares. His prior trades at NXT show a pattern: both measured 90-day outcomes (from May 2024 sales) resulted in declines (-11.3% and -12.3%), marking 2 of 2 prior sells as well-timed under the standard that negative post-sale returns indicate the insider sold ahead of a pullback. Cross-ticker, his record shows a 90-day well-timed rate of 100%, though his average 90-day return across all tickers is -11.8%, consistent with a pattern of selling into strength. Current price of $56.69 sits -8.0% from the 52-week high of $61.59, and NXT has rallied +39.6% over the prior 30 days. Fundamentals show revenue of $679.4M, net income of $115.3M, annual growth of +18.4%, and a low P/E of 10.18, suggesting the company is profitable and growing but trading at a compressed valuation multiple relative to growth.

2025-05-16 Nextracker Inc. NXT
medium
Sell
27,453 shares
$1,651,847
Significance 6/10

Chief Legal Officer sells 27.5K NXT shares at $60.17 after +49.3% 30-day rally; reduces holdings 18.5%.

Bruce Ledesma sold 27,453 shares at $60.17, reducing his position from 148,425 to 120,972 shares (an 18.5% reduction). The sale occurred during a strong price run—NXT has gained 49.3% over 30 days and 25.4% over 90 days, positioning this transaction near the 52-week high of $61.59. Ledesma's cross-ticker track record shows 2 prior sells with a 100.00% well-timed rate at the 90-day mark, and his prior NXT transactions (both on 2024-05-20) also showed negative 90-day returns, consistent with well-timed exit patterns. However, the company's fundamentals remain strong—$679.4M quarterly revenue, +31.4% annual growth, and a reasonable 14.54 P/E ratio—so the sale does not reflect deteriorating business conditions. The timing coincides with elevated valuation momentum rather than fundamental weakness.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access